A detailed history of Beaumont Financial Partners, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Beaumont Financial Partners, LLC holds 8,041 shares of LLY stock, worth $7.12 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
8,041
Previous 8,042 0.01%
Holding current value
$7.12 Million
Previous $2.61 Million 0.27%
% of portfolio
0.25%
Previous 0.23%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$296.48 - $337.87 $296 - $337
-1 Reduced 0.01%
8,041 $2.6 Million
Q2 2022

Aug 04, 2022

SELL
$278.73 - $327.27 $59,090 - $69,381
-212 Reduced 2.57%
8,042 $2.61 Million
Q1 2022

May 09, 2022

SELL
$234.69 - $291.66 $70,876 - $88,081
-302 Reduced 3.53%
8,254 $2.36 Million
Q4 2021

Feb 07, 2022

BUY
$224.85 - $279.04 $1,349 - $1,674
6 Added 0.07%
8,556 $2.36 Million
Q3 2021

Nov 12, 2021

SELL
$221.6 - $272.71 $91,742 - $112,901
-414 Reduced 4.62%
8,550 $1.98 Million
Q2 2021

Aug 04, 2021

BUY
$180.55 - $233.54 $59,762 - $77,301
331 Added 3.83%
8,964 $2.06 Million
Q1 2021

May 04, 2021

SELL
$164.32 - $212.72 $2,629 - $3,403
-16 Reduced 0.18%
8,633 $1.61 Million
Q4 2020

Feb 08, 2021

BUY
$130.46 - $172.63 $45,791 - $60,593
351 Added 4.23%
8,649 $1.46 Million
Q3 2020

Nov 02, 2020

BUY
$146.22 - $169.13 $11,990 - $13,868
82 Added 1.0%
8,298 $1.23 Million
Q2 2020

Aug 05, 2020

SELL
$136.42 - $164.18 $30,967 - $37,268
-227 Reduced 2.69%
8,216 $1.35 Million
Q1 2020

May 08, 2020

BUY
$119.05 - $147.35 $14,881 - $18,418
125 Added 1.5%
8,443 $1.17 Million
Q4 2019

Feb 06, 2020

SELL
$106.92 - $132.43 $320 - $397
-3 Reduced 0.04%
8,318 $1.09 Million
Q3 2019

Nov 06, 2019

BUY
$106.79 - $116.16 $888,599 - $966,567
8,321 New
8,321 $930,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $841B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Beaumont Financial Partners, LLC Portfolio

Follow Beaumont Financial Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Beaumont Financial Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Beaumont Financial Partners, LLC with notifications on news.